As the world economic community grapples with a financial crisis that has shattered the US and European banking industries, constrained credit and unnerved stock markets, business sentiment has plummeted. Despite governmental intervention to shore up liquidity, uncertainty and dread continue to dominate the economic outlook. The fall 2008 IBO Business Climate Survey finds the six-month […]

Donations to charities and other nonprofit institutions that fund medical research could be at risk due to the economic crisis. According to the Center on Philanthropy at the University of Indiana, the level of donations made to charities correlates with the fortunes of the stock markets, but any effects from the current crisis would not […]

Venlo, the Netherlands 10/1/08; Uppsala, Sweden 10/1/08—QIAGEN NV has acquired the assets of the Biosystems business and the remaining 17.5% of Corbett Life Science (see IBO 7/15/08) from Biotage AB for approximately $53 million in cash and performance milestone payments of up to $7 million over four years. The Biosystems business develops and sells the […]

A recent report prepared by the US Government Accountability Office (GAO) found that the FDA’s monitoring of fresh produce is deficient. In fiscal 2007, the FDA spent a minimum of $20.2 million, approximately 3% of its food safety expenditures, on fresh produce oversight. The FDA’s Office of Regulatory Affairs accounted for 82% of this spending, […]

Company Announcements Intellection appointed Beamtech Nordiska AB as its exclusive distributor for Sweden, Scandinavia and the Baltic States. Leica Microsystems CMS GmbH named Dr. Stefan Traeger managing director in June. Leica Microsystems CMS GmbH’s Life Science reorganized into three strategic business units in June: Life Science Research, Clinical Imaging and Nanotechnology. FEI will market and […]

Company Announcements During fiscal year 2008, Applied Biosystems discontinued the manufacture of the 433A Peptide Synthesis and the Procise Protein Sequencing systems, but will continue to provide support for existing systems for five years. Oxford Nanopore Technologies announced in August an exclusive agreement to develop and commercialize nanopore technologies developed at Harvard University, the University […]

A total of 633 biotechnology medicines for more than 100 diseases are currently in development, according to the Pharmaceutical Research and Manufacturers of America (PhRMA). By therapeutic category, with some medicines counted in more than one category, the number of biotech medicines in development for cancer and related conditions, at 254, and infectious disease, at […]